Physician profile
Larry Shuster
NPI 1588630891
$1,056.20
in general payments reported to CMS, 2019-2025
11 companies · $55.02 in 2025
The $55.02 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $66.35 · 2021: $129 · 2022: $179 · 2024: $17.72 · 2025: $55.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.52 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.59 | 2019-2021 | |
| Daiichi Sankyo INC. | $124.99 | 2019 | |
| Janssen Biotech, INC. | $87.57 | 2022-2025 | Tremfya, Stelara, Simponi |
| Merck Sharp & Dohme LLC | $31.97 | 2019 | |
| Ucb, INC. | $22.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.58 | 2022 | |
| Amarin Pharma, INC. | $20.31 | 2020 | |
| Intercept Pharmaceuticals, INC. | $18.20 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.69 | 2020 | |
| Boston Scientific Corporation | $14.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Shuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.